Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, Kappos L.
Hauser SL, et al. Among authors: das gupta a.
Mult Scler. 2022 Sep;28(10):1576-1590. doi: 10.1177/13524585221079731. Epub 2022 Mar 1.
Mult Scler. 2022.
PMID: 35229668
Free PMC article.
Clinical Trial.